Drugs / EXPD-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07684820 | Jun 2026 → Jun 2028 expected | chronic obstructive pulmonary disease | Expedition Therapeutics, Inc | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Fosun Pharma’s Self-Developed Small Molecule Oral Innovative Drug FXS7553 for the Treatment of COPD Successfully Completed Dosed the First Patient in Phase 2 Clinical Trial in China fosunpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXPD-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07684820 ↗ |
| Known as | FXS7553 | “Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks.” NCT07684820 ↗ |
| Route | Oral | “Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks.” NCT07684820 ↗ |